SCHEMBL394707

SCHEMBL394707

CCOC(=O)CC1=CS(=O)(=O)c2cc(NS(C)(=O)=O)ccc2N1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.43
MMP2 P08253 1/20 0.43
MMP13 P45452 1/20 0.43
RECQL P46063 1/20 0.43
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
TSHR P16473 2/20 0.35
HSD17B10 Q99714 2/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
MAPK1 P28482 1/20 0.35
MAPT P10636 2/20 0.34
AURKA O14965 1/20 0.33
AURKB Q96GD4 1/20 0.33
EPHX2 P34913 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
NR3C1 P04150 1/20 0.33
SLC10A2 Q12908 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3924187 0.92 HPGD (0.43) HPGDMMP2MMP13RECQLALDH1A1
SCHEMBL3923974 0.89 BRD4 (0.41) HPGDALDH1A1KDM4ETSHRHSD17B10
SCHEMBL3926561 0.88 EGFR (0.35) HPGDMMP2MMP13RECQLALDH1A1
SCHEMBL3920426 0.87 MAPT (0.44) ALDH1A1KDM4ETSHRHSD17B10LMNA
SCHEMBL3925098 0.87 BRD4 (0.38) ALDH1A1EPHX2NR1H4
SCHEMBL392877 0.85 POLB (0.36) HPGDMMP2MMP13RECQLALDH1A1
SCHEMBL3917990 0.82 ALDH1A1 (0.45) HPGDALDH1A1TSHRHSD17B10LMNA
SCHEMBL13938254 0.82 CA12 (0.40) HPGDRECQLALDH1A1KDM4ETSHR
SCHEMBL14198298 0.80 GAA (0.35) RECQLALDH1A1KDM4ETSHRHSD17B10
SCHEMBL13686400 0.80 TNF (0.38) HPGDALDH1A1KDM4EHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038286-B1 PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS INC (US) 2017-03-08 EP disclosed
EP-2038286-B1 PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS INC (US) 2017-03-08 EP disclosed
EP-2129224-B1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS INC (US) 2016-03-30 EP disclosed
US-9156832-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2015-10-13 US disclosed
US-20150065492-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS INC (US) 2015-03-05 US disclosed
US-8765741-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-20140031346-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2014-01-30 US disclosed
US-8546602-B2 5,6-D hydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2013-10-01 US disclosed
US-20120302744-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2012-11-29 US disclosed
US-8236948-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2012-08-07 US disclosed
US-20080214529-A1 SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2008-09-04 US disclosed
WO-2008073982-A2 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-06-19 WO disclosed
WO-2008073982-A2 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-06-19 WO disclosed
US-20080090814-A1 PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-04-17 US disclosed
US-20080090814-A1 PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-04-17 US disclosed
US-20080031852-A1 PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-02-07 US disclosed
US-20080031852-A1 PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-02-07 US disclosed
US-20080031852-A1 PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-02-07 US disclosed
WO-2007150001-A1 PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2007-12-27 WO disclosed
WO-2007150001-A1 PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090814-A1 PYRIDAZINONE COMPOUNDS HAVCR2, PLPBP, CYP3A43 HPGD 420/4885MMP2 3958/4885MMP13 3688/4885
US-20120302744-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS DPYD, NQO1, MT-ND5 HPGD 222/4885MMP2 4283/4885MMP13 4009/4885
US-20080214529-A1 SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS HAVCR2, ZC3HAV1, NR1H4 HPGD 1556/4885MMP2 4576/4885MMP13 4519/4885
US-20080031852-A1 PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS HAVCR2, CYP4B1, CYP1B1 HPGD 1300/4885MMP2 4737/4885MMP13 4728/4885
US-20140031346-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS HAVCR2, CCR3, C5 HPGD 2729/4885MMP2 4696/4885MMP13 3370/4885
US-20150065492-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS HAVCR2, PYGL, HCCS HPGD 510/4885MMP2 4305/4885MMP13 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.